Massimo Galli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1862755/publications.pdf

Version: 2024-02-01

301 papers 14,116 citations

53 h-index 28297 105 g-index

312 all docs

312 docs citations

312 times ranked

25480 citing authors

#	Article	IF	CITATIONS
1	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	27.0	1,152
2	Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infectious Diseases, The, 2020, 20, 1135-1140.	9.1	1,078
3	Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clinical Infectious Diseases, 2020, 71, 889-890.	5.8	1,057
4	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	28.9	541
5	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	12.6	504
6	Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. Aids, 1999, 13, 465-471.	2.2	279
7	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature Metabolism, 2021, 3, 774-785.	11.9	259
8	COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. Clinical and Experimental Rheumatology, 2020, 38, 337-342.	0.8	249
9	30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacological Research, 2020, 158, 104931.	7.1	206
10	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care, 2020, 43, 2999-3006.	8.6	201
11	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews, 2011, 10, 444-454.	5.8	186
12	Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine, 2020, 27, 100550.	7.1	182
13	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research, 2020, 158, 104899.	7.1	175
14	Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus–Related Symptomatic Mixed Cryoglobulinemias. Archives of Internal Medicine, 2005, 165, 101.	3.8	171
15	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica, 2020, 57, 779-783.	2.5	171
16	Candidemia and invasive candidiasis in adults: A narrative review. European Journal of Internal Medicine, 2016, 34, 21-28.	2.2	166
17	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. Radiologia Medica, 2020, 125, 636-646.	7.7	165
18	Early phylogenetic estimate of the effective reproduction number of SARSâ€CoVâ€2. Journal of Medical Virology, 2020, 92, 675-679.	5.0	159

#	Article	IF	CITATIONS
19	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. Aids, 2011, 25, 1385-1394.	2.2	155
20	Chagas disease in Europe: A review for the internist in the globalized world. European Journal of Internal Medicine, 2017, 43, 6-15.	2.2	148
21	Long-term remission of Kaposi sarcoma–associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood, 2001, 98, 3473-3475.	1.4	147
22	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	4.0	146
23	Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. Aids, 1998, 12, 1631-1637.	2.2	132
24	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. Aids, 2006, 20, 1727-1736.	2.2	127
25	Genomic characterization and phylogenetic analysis of SARSâ€COVâ€⊋ in Italy. Journal of Medical Virology, 2020, 92, 1637-1640.	5.0	116
26	Gender Differences in Antiretroviral Drug–Related Adipose Tissue Alterations. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 58-61.	2.1	111
27	Homozygous î"32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. Aids, 1997, 11, F67-F71.	2.2	108
28	Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2000, 44, 1328-1332.	3.2	95
29	Type 1 Cytokine Production and Low Prevalence of Viral Isolation Correlate with Long-Term Nonprogression in HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1053-1061.	1.1	94
30	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. PLoS ONE, 2010, 5, e13540.	2.5	94
31	Aspergillus meningitis: A rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. Journal of Infection, 2013, 66, 218-238.	3.3	93
32	Kaposi's Sarcoma-Associated Herpesvirus Infection and Multiple Myeloma. Science, 1997, 278, 1969-1973.	12.6	92
33	Body Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 21-31.	2.1	89
34	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood, 2012, 119, 6259-6267.	1.4	83
35	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. Journal of Clinical Medicine, 2020, 9, 1683.	2.4	82
36	Thrombotic Microangiopathy in Patients with Acquired Immunodeficiency Syndrome Before and During the Era of Introduction of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2002, 35, 1534-1540.	5.8	77

#	Article	IF	Citations
37	Role of PCR in Diagnosis and Prognosis of Visceral Leishmaniasis in Patients Coinfected with Human Immunodeficiency Virus Type 1. Journal of Clinical Microbiology, 2001, 39, 357-361.	3.9	75
38	Trends in the Postmortem Diagnosis of Opportunistic Invasive Fungal Infections in Patients With AIDS. American Journal of Clinical Pathology, 2009, 132, 221-227.	0.7	74
39	Enigmatic origin of hepatitis B virus: An ancient travelling companion or a recent encounter?. World Journal of Gastroenterology, 2014, 20, 7622.	3.3	71
40	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. Aids, 2013, 27, 769-779.	2.2	70
41	The Role of Human Herpesvirus 8 and Epstein-Barr Virus in the Pathogenesis of Giant Lymph Node Hyperplasia (Castleman's Disease). Clinical Infectious Diseases, 1996, 22, 1120-1121.	5.8	68
42	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. Vaccines, 2020, 8, 471.	4.4	68
43	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	1.9	67
44	Incidence of Adipose Tissue Alterations in First-Line Antiretroviral Therapy. Archives of Internal Medicine, 2002, 162, 2621.	3.8	66
45	High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology, 2007, 365, 113-124.	2.4	64
46	Increased Mitochondrial Dna Content in Peripheral Blood Lymphocytes from HIV-Infected Patients with Lipodystrophy. Antiviral Therapy, 2003, 8, 315-321.	1.0	64
47	Lowâ€Dose Prolonged Intermittent Interleukinâ€2 Adjuvant Therapy: Results of a Randomized Trial among Human Immunodeficiency Virus–Positive Patients with Advanced Immune Impairment. Journal of Infectious Diseases, 2002, 186, 606-616.	4.0	63
48	Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based Survey. JMIR Public Health and Surveillance, 2020, 6, e21866.	2.6	63
49	Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy: Table 1. Rheumatology, 2016, 55, 2084-2085.	1.9	62
50	Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. Journal of Infection, 2020, 81, e10-e12.	3.3	58
51	Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. Aids, 2006, 20, 567-574.	2.2	56
52	Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. Journal of Antimicrobial Chemotherapy, 2012, 67, 460-464.	3.0	55
53	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015, 12, 33.	2.0	55
54	Spatial and Temporal Dynamics of Hepatitis B Virus D Genotype in Europe and the Mediterranean Basin. PLoS ONE, 2012, 7, e37198.	2.5	55

#	Article	IF	CITATIONS
55	Body Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 21-31.	2.1	54
56	Population Dynamics of HIV-1 Subtype B in a Cohort of Men-Having-Sex-With-Men in Rome, Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 156-160.	2.1	53
57	Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infection, Genetics and Evolution, 2011, 11, 646-653.	2.3	53
58	Detection of Hepatitis C Virus RNA in CD19 Peripheral Blood Mononuclear Cells of Chronically Infected Patients. Journal of Infectious Diseases, 1997, 176, 1209-1214.	4.0	52
59	Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. Journal of Clinical Lipidology, 2021, 15, 68-78.	1.5	52
60	PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	5.0	51
61	Prevalence and outcome of silent hypoxemia in COVID-19. Minerva Anestesiologica, 2021, 87, 325-333.	1.0	49
62	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. Aids, 2008, 22, 1769-1778.	2.2	48
63	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	2.0	48
64	Reconstructing the recent West Nile virus lineage 2 epidemic in Europe and Italy using discrete and continuous phylogeography. PLoS ONE, 2017, 12, e0179679.	2.5	48
65	Hepatitis C virus and mixed cryoglobulinaemias. Lancet, The, 1992, 339, 989.	13.7	47
66	CD4 cell counts at the third month of HAART may predict clinical failure. Aids, 1999, 13, 1669-1676.	2.2	47
67	Liver-related death among HIV/hepatitis C virus-co-infected individuals. Aids, 2015, 29, 1205-1215.	2.2	46
68	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. Viruses, 2020, 12, 798.	3.3	46
69	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. Antiviral Therapy, 2011, 16, 1103-1112.	1.0	45
70	Trends and Predictors of Non–AIDS-Defining Cancers in Men and Women With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 414-420.	2.1	45
71	Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. Aids, 1996, 10, 23-30.	2.2	44
72	Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. Aids, 2001, 15, 965-974.	2.2	44

#	Article	IF	CITATIONS
73	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. Journal of Autoimmunity, 2015, 63, 88-93.	6.5	41
74	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Multiple Sclerosis Journal, 2021, 27, 347-359.	3.0	41
75	[13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. Journal of Antimicrobial Chemotherapy, 2005, 55, 84-89.	3.0	40
76	Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience. International Journal of Cardiology, 2021, 323, 276-280.	1.7	40
77	Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. Virology, 2008, 380, 84-90.	2.4	38
78	Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of \hat{l}^2 chemokines and RNases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5411-5416.	7.1	38
79	Human-to-Cat SARS-CoV-2 Transmission: Case Report and Full-Genome Sequencing from an Infected Pet and Its Owner in Northern Italy. Pathogens, 2021, 10, 252.	2.8	38
80	Fungal Endocarditis Observed Over an 8-Year Period and a Review of the Literature. Mycopathologia, 2014, 178, 37-51.	3.1	37
81	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmunity Reviews, 2014, 13, 609-614.	5.8	37
82	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International, 2020, 40, 1545-1555.	3.9	37
83	Effect of Antioxidants on Mitochondrial Function in HIV-1–Related Lipoatrophy: A Pilot Study. AIDS Research and Human Retroviruses, 2010, 26, 1207-1214.	1.1	35
84	Compartmentalization of Hepatitis C Virus Quasispecies in Blood Mononuclear Cells of Patients with Mixed Cryoglobulinemic Syndrome. Journal of Virology, 2005, 79, 9145-9156.	3.4	34
85	Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events. PLoS ONE, 2013, 8, e80242.	2.5	34
86	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. Aids, 2010, 24, 1455-1460.	2.2	33
87	Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Journal of Antimicrobial Chemotherapy, 2010, 65, 735-740.	3.0	33
88	Origin, evolution, and phylogeography of recent epidemic CHIKV strains. Infection, Genetics and Evolution, 2012, 12, 392-398.	2.3	33
89	4 The syndrome of acquired glucocorticoid resistance in HIV infection. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 777-787.	1.0	32
90	HIV Type 1 Phenotype Correlates with the Stage of Infection in Vertically Infected Children. AIDS Research and Human Retroviruses, 1996, 12, 1247-1253.	1.1	32

#	Article	IF	CITATIONS
91	Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmunity Reviews, 2019, 18, 778-785.	5.8	32
92	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmunity Reviews, 2020, 19, 102574.	5.8	32
93	Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in <i>Pol</i> Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected Individuals. Antiviral Therapy, 2000, 5, 7-14.	1.0	32
94	Evolutionary Dynamics of the Lineage 2 West Nile Virus That Caused the Largest European Epidemic: Italy 2011–2018. Viruses, 2019, 11, 814.	3.3	31
95	Rapid COVID-19 Screening Based on Self-Reported Symptoms: Psychometric Assessment and Validation of the EPICOVID19 Short Diagnostic Scale. Journal of Medical Internet Research, 2021, 23, e23897.	4.3	31
96	Combination of CCR5 and CXCR4 Inhibitors in Therapy of Human Immunodeficiency Virus Type 1 Infection: In Vitro Studies of Mixed Virus Infections. Journal of Virology, 2000, 74, 9328-9332.	3.4	30
97	Comparison of the <i>In Vivo</i> Pharmacokinetics and <i>In Vitro</i> Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing. Antimicrobial Agents and Chemotherapy, 2012, 56, 6132-6136.	3.2	30
98	Reconstruction of the epidemic history of hepatitis B virus genotype D in Albania. Infection, Genetics and Evolution, 2012, 12, 291-298.	2.3	30
99	Phylogeography and phylodynamics of European genotype 3 hepatitis E virus. Infection, Genetics and Evolution, 2014, 25, 138-143.	2.3	30
100	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	3.0	30
101	The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. Medicine (United States), 2020, 99, e22433.	1.0	30
102	Cryoglobulinaemia and serological markers of hepatitis viruses. Lancet, The, 1991, 338, 758-759.	13.7	29
103	Identification of Two Distinct Subsets of Longâ€Term Nonprogressors with Divergent Viral Activity by Stromalâ€Derived Factor 1 Chemokine Gene Polymorphism Analysis. Journal of Infectious Diseases, 1999, 180, 285-289.	4.0	29
104	Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men. Infection, Genetics and Evolution, 2014, 23, 176-181.	2.3	29
105	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. Frontiers in Immunology, 2021, 12, 656362.	4.8	29
106	High prevalence of human T-lymphotropic virus type 1 (HTLV-1) in immigrant male-to-female transsexual sex workers with HIV-1 infection. Journal of Medical Virology, 2004, 74, 207-215.	5.0	28
107	Association Between Smoking and SARS-CoV-2 Infection: Cross-sectional Study of the EPICOVID19 Internet-Based Survey. JMIR Public Health and Surveillance, 2021, 7, e27091.	2.6	28
108	Prevalence of Multiple Dideoxynucleoside Analogue Resistance (MddNR) in a Multicenter Cohort of HIV-1–Infected Italian Patients With Virologic Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 232-240.	2.1	26

#	Article	IF	CITATIONS
109	Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages? PLoS ONE, 2015, 10, e0123670.	2.5	26
110	Prevalence of Multiple Dideoxynucleoside Analogue Resistance (MddNR) in a Multicenter Cohort of HIV-1–Infected Italian Patients With Virologic Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 232-240.	2.1	25
111	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 86-92.	2.1	25
112	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. Journal of Autoimmunity, 2021, 116, 102545.	6.5	25
113	Retinal vessels modifications in acute and post-COVID-19. Scientific Reports, 2021, 11, 19373.	3.3	25
114	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clinical and Experimental Rheumatology, 2012, 30, S48-52.	0.8	25
115	Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. Aids, 2004, 18, 574-576.	2.2	24
116	Profile of infective endocarditis observed from 2003 - 2010 in a single center in Italy. BMC Infectious Diseases, 2013, 13, 545.	2.9	24
117	Candidaemia Observed at a University Hospital in Milan (Northern Italy) and Review of Published Studies from 2010 to 2014. Mycopathologia, 2014, 178, 227-241.	3.1	24
118	Reliable timescale inference of HBV genotype A origin and phylodynamics. Infection, Genetics and Evolution, 2015, 32, 361-369.	2.3	24
119	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS oVâ€2 infection: A retrospective cohort study. Journal of Medical Virology, 2021, 93, 1421-1427.	5.0	24
120	Clinical and immunological aspects of HIV infection in drug addicts. Clinical Immunology and Immunopathology, 1989, 50, S166-S176.	2.0	23
121	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Frontiers in Immunology, 2019, 10, 233.	4.8	23
122	Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. Aids, 2004, 18, 211-216.	2.2	22
123	Reversible Posterior Leukoencephalopathy Syndrome in 2 HIV-Infected Patients Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, e19-e22.	5 . 8	22
124	Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infection, Genetics and Evolution, 2013, 17, 223-230.	2.3	22
125	Heterogeneity of COVID-19 outbreak in Italy. Acta Biomedica, 2020, 91, 31-34.	0.3	22
126	High Prevalence of False-Negative Anti-HTLV Type I/II Enzyme-Linked Immunosorbent Assay Results in HIV Type 1-Positive Patients. AIDS Research and Human Retroviruses, 1997, 13, 1141-1146.	1.1	21

#	Article	IF	CITATIONS
127	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. Journal of Antimicrobial Chemotherapy, 2004, 53, 464-468.	3.0	21
128	Liver-Related Factors Associated with Low Vitamin D Levels in HIV and HIV/HCV Coinfected Patients and Comparison to General Population. Current HIV Research, 2011, 9, 186-193.	0.5	21
129	Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate?. Pharmacological Research, 2021, 164, 105403.	7.1	21
130	Abacavir Hypersensitivity Reaction after Switching from the Twice-Daily to the Once-Daily Formulation. AIDS Patient Care and STDs, 2007, 21, 1-3.	2.5	20
131	Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent inference. Infection, Genetics and Evolution, 2010, 10, 215-220.	2.3	20
132	Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Digestive and Liver Disease, 2022, 54, 237-242.	0.9	20
133	Age-Related Changes in Clinical Presentation of Covid-19: the EPICOVID19 Web-Based Survey. European Journal of Internal Medicine, 2021, 86, 41-47.	2.2	20
134	Human T-Lymphotropic Virus Type 2 (HTLV-2) Provirus in Circulating Cells of the Monocyte/Macrophage Lineage in Patients Dually Infected with Human Immunodeficiency Virus Type 1 and HTLV-2 and Having Predominantly Sensory Polyneuropathy. Journal of Virology, 1998, 72, 7664-7668.	3.4	20
135	Bayesian Phylogeography of Crimean-Congo Hemorrhagic Fever Virus in Europe. PLoS ONE, 2013, 8, e79663.	2.5	20
136	Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes, 2022, 71, 1800-1806.	0.6	20
137	Hepatitis B virus genotype distribution in HIV-1 coinfected patients. Gastroenterology, 2003, 125, 1559-1560.	1.3	19
138	Pandemic influenza vaccine in adult HIV-1-infected patients. Aids, 2010, 24, 2142-2143.	2.2	19
139	Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Case Control Evaluation and Review of the Literature. AIDS Patient Care and STDs, 2010, 24, 697-703.	2.5	19
140	High Frequency of Adverse Reactions and Discontinuation With Benznidazole Treatment for Chronic Chagas Disease in Milan, Italy. Clinical Infectious Diseases, 2015, 60, 1873-1875.	5.8	19
141	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). Viruses, 2021, 13, 1032.	3.3	19
142	Within-Host Dynamics of the Hepatitis C Virus Quasispecies Population in HIV-1/HCV Coinfected Patients. PLoS ONE, 2011, 6, e16551.	2.5	19
143	Reconstruction of the Evolutionary Dynamics of the A(H1N1)pdm09 Influenza Virus in Italy during the Pandemic and Post-Pandemic Phases. PLoS ONE, 2012, 7, e47517.	2.5	18
144	Persisting HIV-1 Replication Triggered by Acute Hepatitis a Virus Infection. Antiviral Therapy, 2000, 5, 15-17.	1.0	18

#	Article	IF	CITATIONS
145	Establishment of an ex vivo model of monocytes-derived macrophages differentiated from peripheral blood mononuclear cells (PBMCs) from HIV-1 transgenic rats. Molecular Immunology, 2004, 41, 979-984.	2.2	17
146	Reconstruction of the evolutionary dynamics of the hepatitis C virus 1b epidemic in Turkey. Infection, Genetics and Evolution, 2011, 11, 863-868.	2.3	17
147	Phylogeographic Reconstruction of HIV Type 1B in Montenegro and the Balkan Region. AIDS Research and Human Retroviruses, 2012, 28, 1280-1284.	1.1	17
148	Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatric Infectious Disease Journal, 1997, 16, 205-211.	2.0	17
149	Myasthenia gravis with a monoclonal gammopathy. Journal of the Neurological Sciences, 1980, 45, 103-108.	0.6	16
150	Frequent Detection of Antibodies against HTLV Antigens in Patients with AIDS-Related Non-Hodgkin Lymphoma. AIDS Research and Human Retroviruses, 1995, 11, 823-827.	1.1	16
151	Thalidomide in the Treatment of Chronic Hepatitis C Unresponsive to Alfa-Interferon and Ribavirin. American Journal of Gastroenterology, 2006, 101, 399-402.	0.4	16
152	Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of human immunodeficiency virus type 1 unique recombinant forms. Journal of General Virology, 2008, 89, 3119-3125.	2.9	16
153	Description of a "Trans-Saharan―Strain of Human T-Lymphotropic Virus Type 1 in West Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 269-273.	2.1	16
154	Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy. PLoS ONE, 2010, 5, e15663.	2.5	16
155	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. Journal of Antimicrobial Chemotherapy, 2012, 67, 2236-2242.	3.0	16
156	HTLV Infection in ELISA-Negative Blood Donors. AIDS Research and Human Retroviruses, 1996, 12, 737-740.	1.1	15
157	Reduced Levels of CD4 Cell Spontaneous Apoptosis in Human Immunodeficiency Virus–Infected Patients with Discordant Response to Protease Inhibitors. Journal of Infectious Diseases, 2002, 186, 143-144.	4.0	15
158	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine, 2017, 84, 525-530.	1.6	15
159	Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. European Journal of Gastroenterology and Hepatology, 2018, 30, 1208-1215.	1.6	15
160	Detecting HCV infection by means of mass population SARS-CoV-2 screening: A pilot experience in Northern Italy. Journal of Hepatology, 2021, 75, 484-486.	3.7	15
161	Soluble HIV suppressive factors: more than one Holy Grail?. Trends in Immunology, 1996, 17, 297-298.	7. 5	14
162	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. Journal of Antimicrobial Chemotherapy, 2011, 66, 192-200.	3.0	14

#	Article	IF	CITATIONS
163	Expression of Interleukin-15 and Interleukin-15Rî± in Monocytes of HIV Type 1-Infected Patients with Different Courses of Disease Progression. AIDS Research and Human Retroviruses, 2012, 28, 693-701.	1.1	14
164	Novel genetic association of TNF- $\hat{l}\pm$ -238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. International Journal of Infectious Diseases, 2013, 17, e845-e850.	3.3	14
165	Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. Aids, 2003, 17, 257-260.	2.2	14
166	Serum $2\hat{a}\in^2$ - $5\hat{a}\in^2$ -Oligoadenylate Synthetase Levels and Clinical Response to Interferon- \hat{l}^2 Therapy in Women with Genital Human Papillomavirus Infection. Journal of Infectious Diseases, 1994, 169, 1112-1115.	4.0	13
167	Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. Aids, 2000, 14, 1101-1110.	2.2	13
168	Resistance to Fas-Mediated Apoptosis of Human T-Cell Lines Expressing Human T-Lymphotropic Virus Type-2 (HTLV-2) Tax Protein. Virology, 2001, 281, 43-50.	2.4	13
169	In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure. Journal of Clinical Microbiology, 2001, 39, 1124-1129.	3.9	13
170	Diffusion and transmission of carbapenem-resistant Klebsiella pneumoniae in the medical and surgical wards of a university hospital in Milan, Italy. Journal of Infection and Public Health, 2016, 9, 24-33.	4.1	13
171	Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 315-321.	2.1	13
172	Epidemiological trends of infective endocarditis in a single center in Italy between 2003–2015. Infectious Diseases, 2018, 50, 749-756.	2.8	13
173	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. International Journal of Infectious Diseases, 2020, 92, 62-68.	3.3	13
174	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. New Microbiologica, 2016, 39, 93-109.	0.1	13
175	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. Antiviral Therapy, 2004, 9, 603-614.	1.0	13
176	Retrobulbar optic neuritis in a patient with acute type B hepatitis. Journal of the Neurological Sciences, 1986, 72, 195-200.	0.6	12
177	Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. British Journal of Haematology, 1998, 102, 1187-1196.	2.5	12
178	Maintenance of Breast Size Reduction After Mastoplasty and Switch to a Protease Inhibitor-Sparing Regimen in an HIV-Positive Woman with Highly Active Antiretroviral Therapy-Associated Massive Breast Enlargement. AIDS Patient Care and STDs, 2002, 16, 307-311.	2.5	12
179	Controversy concerning role of ultrasonographic lipoatrophy assessments in HIV patients. Aids, 2006, 20, 789-790.	2.2	12
180	Risk factors for HIV/AIDS in a low HIV prevalence site of subâ€Saharan Africa. Tropical Medicine and International Health, 2007, 12, 1011-1017.	2.3	12

#	Article	IF	Citations
181	Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau. Journal of Infection, 2010, 61, 391-398.	3.3	12
182	Transmission of Resistant HIV Type 1 Variants and Epidemiological Chains in Italian Newly Diagnosed Individuals. AIDS Research and Human Retroviruses, 2012, 28, 857-865.	1.1	12
183	Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy. Internal and Emergency Medicine, 2021, 16, 1173-1181.	2.0	12
184	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. PLoS ONE, 2020, 15, e0242278.	2.5	12
185	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. Lancet Infectious Diseases, The, 2022, 22, 649-656.	9.1	12
186	Increased CD36 expression on circulating monocytes during HIV infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 310-3.	2.1	12
187	Il-7/Il-7 Receptor System Regulation following Il-2 Immunotherapy in HIV-Infected Patients. Antiviral Therapy, 2004, 9, 447-452.	1.0	12
188	Changes in the Incidence of Severe Thrombocytopenia and Its Predisposing Conditions in HIV-Infected Patients Since the Introduction of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 493-498.	2.1	11
189	Severe Plasmodium falciparum malaria in the intensive care unit: A 6-year experience in Milano, Italy. Travel Medicine and Infectious Disease, 2017, 17, 43-49.	3.0	11
190	Is imported onchocerciasis a truly rare entity? Case report and review of the literature. Travel Medicine and Infectious Disease, 2017, 16, 11-17.	3.0	11
191	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART EBioMedicine, 2021, 66, 103306.	6.1	11
192	Stratification of the risk of developing severe or lethal Covid-19 using a new score from a large Italian population: a population-based cohort study. BMJ Open, 2021, 11, e053281.	1.9	11
193	Altered Signaling Lymphocytic Activation Molecule (SLAM) Expression in HIV Infection and Redirection of HIV-Specific Responses via SLAM Triggering. Clinical Immunology, 1999, 92, 276-284.	3.2	10
194	Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. Journal of Clinical Virology, 2004, 29, 27-32.	3.1	10
195	Trends in hospital admissions at a Department for Infectious Diseases in Italy from 1995 to 2011 and implications for health policies. BMC Public Health, 2014, 14, 980.	2.9	10
196	Drug-induced liver steatosis in patients with HIV infection. Pharmacological Research, 2019, 145, 104267.	7.1	10
197	SARSâ€CoVâ€2 reinfection in a cancer patient with a defective neutralizing humoral response. Journal of Medical Virology, 2021, 93, 6444-6446.	5.0	10
198	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS ONE, 2017, 12, e0171611.	2.5	10

#	Article	IF	CITATIONS
199	Influenza Vaccination Uptake in the General Italian Population during the 2020–2021 Flu Season: Data from the EPICOVID-19 Online Web-Based Survey. Vaccines, 2022, 10, 293.	4.4	10
200	Body Habitus Alterations in HIV-Infected Women Treated with Combined Antiretroviral Therapy. AIDS Patient Care and STDs, 2000, 14, 595-601.	2.5	9
201	Telbivudine in the Treatment of Chronic Hepatitis B: Experience in HIV Type-1-Infected Patients Naive for Antiretroviral Therapy. Antiviral Therapy, 2009, 14, 869-872.	1.0	9
202	Short Communication: Impact of Hepatitis C Viral Clearance on CD4+ T-Lymphocyte Course in HIV/HCV-Coinfected Patients Treated with Pegylated Interferon Plus Ribavirin. AIDS Research and Human Retroviruses, 2012, 28, 989-993.	1.1	9
203	Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy. PLoS ONE, 2021, 16, e0246513.	2.5	9
204	A Nonparametric Procedure for Defining a New Humoral Immunologic Profile in a Pilot Study on HIV Infected Patients. PLoS ONE, 2013, 8, e58768.	2.5	9
205	Mortality among Italians and immigrants with COVID-19 hospitalised in Milan, Italy: data from the Luigi Sacco Hospital registry. BMC Infectious Diseases, 2022, 22, 63.	2.9	9
206	HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 67-76.	0.8	9
207	Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. Antiviral Therapy, 2003, 8, 347-354.	1.0	9
208	Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. Antiviral Therapy, 2016, 21, 529-534.	1.0	8
209	Distribution of Marburg virus in Africa: An evolutionary approach. Infection, Genetics and Evolution, 2016, 44, 8-16.	2.3	8
210	Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World Journal of Biological Psychiatry, 2020, 21, 651-657.	2.6	8
211	Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey. Vaccines, 2020, 8, 669.	4.4	8
212	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). Internal and Emergency Medicine, 2021, 16, 149-156.	2.0	8
213	Predicting Severe/Critical Outcomes in Patients With SARS-CoV2 Pneumonia: Development of the prediction seveRe/critical ouTcome in COVID-19 (CRITIC) Model. Frontiers in Medicine, 2021, 8, 695195.	2.6	8
214	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 1018-1028.	0.8	8
215	Thymostimulin treatment in AIDS-related complex. Clinical Immunology and Immunopathology, 1988, 47, 253-261.	2.0	7
216	Aminooxypentane-RANTES, an Inhibitor of R5 Human Immunodeficiency Virus Type 1, Increases the Interferon gamma to Interleukin 10 Ratio without Impairing Cellular Proliferation. AIDS Research and Human Retroviruses, 1999, 15, 861-867.	1.1	7

#	Article	IF	Citations
217	Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?. Aids, 2004, 18, 1224-1226.	2.2	7
218	Increased CD36 Expression in Vertically Human Immunodeficiency Virus-Infected Children Unrelated to Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2005, 24, 576-577.	2.0	7
219	Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 149-150.	5.8	7
220	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. ClinicoEconomics and Outcomes Research, 2014, 6, 409.	1.9	7
221	When food can make the difference: The case of elvitegravir-based co-formulation. International Journal of Pharmaceutics, 2016, 512, 301-304.	5.2	7
222	Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV Eradication. American Journal of Gastroenterology, 2017, 112, 1753-1754.	0.4	7
223	Lung ultrasound in the management of pneumocystis pneumonia: A case series. International Journal of STD and AIDS, 2019, 30, 188-193.	1.1	7
224	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. BMC Medicine, 2022, 20, 52.	5 . 5	7
225	Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. Antiviral Therapy, 2001, 6, 41-46.	1.0	7
226	Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVIDâ€19. Diabetes/Metabolism Research and Reviews, 2022, 38, .	4.0	7
227	Pulmonary Candidiasis in a Heroin Addict: Some Remarks on its Aetiology and Pathogenesis. Addiction, 1985, 80, 103-104.	3.3	6
228	Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. Aids, 2003, 17, S155-S161.	2.2	6
229	Comparability of Echographic and Tomographic Assessments of Body Fat Changes Related to the HIV Associated Adipose Redistribution Syndrome (HARS) in Antiretroviral Treated Patients. Ultrasound in Medicine and Biology, 2008, 34, 1043-1048.	1.5	6
230	Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. Journal of Antimicrobial Chemotherapy, 2013, 68, 1206-1207.	3.0	6
231	Pain management in cryoglobulinaemic syndrome. Best Practice and Research in Clinical Rheumatology, 2015, 29, 77-89.	3.3	6
232	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. Frontiers in Microbiology, 2019, 10, 769.	3.5	6
233	Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference?. Health Policy, 2021, 125, 1580-1586.	3.0	6
234	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. Scientific Reports, 2022, 12, 5736.	3.3	6

#	Article	IF	CITATIONS
235	New Macrocyclic Amines Showing Activity as HIV Entry Inhibitors Against Wild Type and Multi-Drug Resistant Viruses. Molecules, 2009, 14, 1927-1937.	3.8	5
236	Bayesian skyline plot inference of the Toscana virus epidemic: A decline in the effective number of infections over the last 30 years. Infection, Genetics and Evolution, 2009, 9, 562-566.	2.3	5
237	Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC Infectious Diseases, 2012, 12, 179.	2.9	5
238	Is Chewed Raltegravir an Option to Care for HIV-Infected Patients With Active Tuberculosis?. Clinical Infectious Diseases, 2013, 57, 480-481.	5.8	5
239	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load â‰ 5 0 copies/mL in the observational setting. Antiviral Therapy, 2013, 19, 319-324.	1.0	5
240	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV–HIV Coinfection in Interferon-Naive Patients. Antiviral Therapy, 2014, 19, 735-745.	1.0	5
241	Reconstruction of the Evolutionary Dynamics of A(H3N2) Influenza Viruses Circulating in Italy from 2004 to 2012. PLoS ONE, 2015, 10, e0137099.	2.5	5
242	Hepatitis B virus genotype and subgenotype prevalence and distribution in Montenegro. Journal of Medical Virology, 2015, 87, 807-813.	5.0	5
243	<p>Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects</p> . Drug Design, Development and Therapy, 2019, Volume 13, 2271-2282.	4.3	5
244	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	2.5	5
245	Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 149-154.	0.8	5
246	Structural skull defects in type IV Ehlers-Danlos syndrome. British Journal of Dermatology, 1984, 110, 122-124.	1.5	4
247	Patterns ofin VitroAnti-Human Immunodeficiency Virus Type 1 Antibody Production in Long-Term Nonprogressors. Clinical Immunology and Immunopathology, 1997, 85, 320-323.	2.0	4
248	Phylogeny of Human T Cell Lymphotropic Virus Type 1 in Peru: A High Degree of Evolutionary Relatedness with South African Isolates. AIDS Research and Human Retroviruses, 2007, 23, 1146-1149.	1.1	4
249	Tubercular Gluteus Abscesses: A Return to The Early 20th Century or a Consequence of New, Unprecedented Behaviors?. Clinical Infectious Diseases, 2011, 52, 1082-1083.	5.8	4
250	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19769.	3.0	4
251	Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. Antiviral Therapy, 2014, 20, 449-451.	1.0	4
252	<scp>OPERA</scp> : responses to peginterferon and ribavirin therapy in a subgroup of interferonâ€naÃ⁻ve patients with <scp>HIV</scp> / <scp>HCV</scp> genotype 2/3 coâ€infection in Italy. Liver International, 2015, 35, 120-129.	3.9	4

#	Article	IF	Citations
253	Epidemiological and clinical characteristics of imported malaria in adults in Milan, Italy, 2010–2015. European Journal of Internal Medicine, 2018, 57, e13-e16.	2.2	4
254	Contribution of transgender sex workers to the complexity of the HIV-1 epidemic in the metropolitan area of Milan. Sexually Transmitted Infections, 2020, 96, 451-456.	1.9	4
255	SARS-COV-2 infection: Across the border into the family. Travel Medicine and Infectious Disease, 2020, 36, 101784.	3.0	4
256	The cryoglobulinemic syndrome. Research in Clinic and Laboratory, 1986, 16, 269-274.	0.3	4
257	Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study. International Journal of Environmental Research and Public Health, 2022, 19, 1274.	2.6	4
258	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 72-77.	0.8	4
259	Short Communication : Lack of <i>in Vitro</i> Anti-gp160 Antibody Production Is a Correlate of Nonprogression among HIV Type 1-Infected Individuals. AIDS Research and Human Retroviruses, 1998, 14, 1341-1343.	1.1	3
260	Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir. Journal of Clinical Virology, 2008, 41, 154-159.	3.1	3
261	Subtype Assignment and Phylogenetic Analysis of HIV Type 1 Strains in Patients from Swaziland. AIDS Research and Human Retroviruses, 2008, 24, 323-325.	1.1	3
262	Proven Intra and Interobserver Reliability in the Echographic Assessments of Body Fat Changes Related to HIV Associated Adipose Redistribution Syndrome (HARS). Current HIV Research, 2008, 6, 276-278.	0.5	3
263	Dating the origin and dispersal of Human Papillomavirus type 16 on the basis of ancestral human migrations. Infection, Genetics and Evolution, 2016, 39, 258-264.	2.3	3
264	Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antiviral Therapy, 2003, 8, 347-54.	1.0	3
265	Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patients With Poor Immunologic Response to HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 277-278.	2.1	2
266	Analysis of theenvV3 Sequences Obtained from Patients with HIV Type 1 Infection Treated with the Immune Modulant Agent Tucaresol. AIDS Research and Human Retroviruses, 2005, 21, 815-819.	1.1	2
267	Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results. Current HIV Research, 2011, 9, 625-629.	0.5	2
268	Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers. Therapeutic Drug Monitoring, 2015, 37, 119-125.	2.0	2
269	Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients. Antiviral Research, 2016, 129, 52-57.	4.1	2
270	Origin and evolutionary dynamics of Hepatitis B virus (HBV) genotype E in Madagascar. Pathogens and Global Health, 2017, 111, 23-30.	2.3	2

#	Article	IF	CITATIONS
271	Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics, 2021, 11, 327.	2.6	2
272	Are Epidemiological Estimates Able to Describe the Ability of Health Systems to Cope with COVID-19 Epidemic?. Risk Management and Healthcare Policy, 2021, Volume 14, 2221-2229.	2.5	2
273	Chagas disease in Italy: the study's contribution of Italian researchers. Panminerva Medica, 2020, 61, 464-472.	0.8	2
274	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. Clinical and Experimental Rheumatology, 2020, 38, 245-256.	0.8	2
275	Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy. Vaccines, 2022, 10, 623.	4.4	2
276	Specific IgE response in dracunculiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, 79, 283.	1.8	1
277	Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. Future Virology, 2011, 6, 521-533.	1.8	1
278	HCV-Negative Mixed Cryoglobulinemia: Facts and Fancies. , 2012, , 239-243.		1
279	Critically ill patients at risk of invasive candidiasis: The "dilemma―of the best antifungal treatment strategy. European Journal of Internal Medicine, 2017, 37, e20-e21.	2.2	1
280	Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Na $\tilde{\mathbb{A}}$ -ve HIV patients. Brain Research Bulletin, 2022, 181, 129-143.	3.0	1
281	Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 149-154.	0.8	1
282	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695-695.	0.8	1
283	Immunological Features of Nonhealing Midline Granuloma. Orl, 1986, 48, 256-260.	1.1	0
284	Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects. Journal of Antimicrobial Chemotherapy, 2002, 49, 427-429.	3.0	0
285	Absence of New Thymidine-Associated Mutations and Evidence of an Immune Virologic Response Over a 12-Month Period in a Cohort of Antiretroviral-Experienced HIV-1-Infected Subjects Treated With Tenofovir Combination Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 238-241.	2.1	0
286	Favorable Therapeutic Response with an Antiretroviral Salvage Regimen in an HIV-1-Positive Subject Infected with a CRF11-cpx Virus. AIDS Research and Human Retroviruses, 2014, 30, 480-483.	1.1	0
287	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metabolism and Personalized Therapy, 2017, 32, 115-117.	0.6	0
288	Pneumocystis carinii pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. Aids, 2003, 17, 940-941.	2.2	0

#	Article	IF	CITATIONS
289	HBV/HCV Co-infection and Mixed Cryoglobulinemia. , 2012, , 227-231.		O
290	Incidence and Characteristics of Non-Hodgkin's Lymphomas in HCV-Positive Patients with Mixed Cryoglobulinemia. , 2012, , 273-275.		0
291	HBV Virus in the Future. , 2016, , 31-64.		O
292	The value of lamp to rule out imported malaria diagnosis: a retrospective observational study in Milan, Italy. Infectious Diseases, 2022, 54, 410-417.	2.8	0
293	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 695.	0.8	0
294	538â€∫Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospital during COVID-19 pandemic in Italy. European Heart Journal Supplements, 2021, 23, .	0.1	0
295	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15, e0242278.		0
296	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15 , e0242278.		0
297	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15, e0242278.		0
298	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15 , e0242278.		0
299	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15, e0242278.		0
300	Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?. , 2020, 15, e0242278.		0
301	Vulnerability Predictors of Post-Vaccine SARS-CoV-2 Infection and Disease—Empirical Evidence from a Large Population-Based Italian Platform. Vaccines, 2022, 10, 845.	4.4	O